心脏通道病的性别相关差异:对临床实践的影响
Babken Asatryan1, Lauren Yee2, Yael Ben-Haim3,4
1Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland (B.A., S.D., H.S., L.R., H.T., T.R., K.E.O.).
Circulation
|February 15, 2021
概括
性别影响心脏通道病变,如长QT综合征和布鲁加达综合征,男性和女性之间的疾病风险和结果不同. 了解这些性别差异对于个性化的患者护理至关重要.
科学领域:
- 心脏病学
- 遗传学
- 内分泌学
背景情况:
- 尽管有相同的遗传倾向,但心脏通道病在患病率,表现和结果上表现出与性别有关的差异.
- 诸如先天性长QT综合征和布鲁加达综合征等疾病显示出不同性别的心律失常和突然心脏死亡风险.
- 这些差异是由调节心脏离子通道的年龄和性别激素影响的.
研究的目的:
- 审查有关心脏通道病的性别差异的现有证据.
- 突出临床影响和识别知识差距.
- 强调需要进行性别特定的研究和报告.
主要方法:
- 对有关心脏通道病的性别差异研究的文献综述.
- 对临床数据和实验结果的分析.
- 对遗传,荷尔蒙和环境因素的综合证据.
主要成果:
- 成年女性面临先天性长QT综合征的更高风险,而成年男性主要受到布鲁加达综合征的影响.
- 在几种通道病症中发现了性别特异性预测结果.
- 性激素通过影响心脏离子通道功能来发挥差异作用.
结论:
- 性别特定的因素显著影响心脏通道病的风险和结果.
- 需要进一步研究以了解这些差异背后的机制.
- 改善个性化的患者护理和与性别相关的参数报告是必不可少的.
更多相关视频
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
146
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
146
Electrophysiology of Normal Cardiac Rhythm
8.1K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
8.1K
Mechanism of Cardiac Arrhythmias
1.4K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
Pathophysiology of Cardiac Performance
1.1K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.1K
Dysrhythmias VI: Management of Dysrhythmias
223
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
223


